RETRACTED: Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases
Authors:
- 26 February 2025
- journal article
- retracted article
- Published by Elsevier in Cancer Genetics
- Vol. 294-295, 47-56
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Genetic expression in cancer research: Challenges and complexityGene Reports, 2024
- A handheld isothermal fluorescence detector for duplex visualization of aquatic pathogens via enhanced one-pot LAMP-PfAgo assayBiosensors and Bioelectronics, 2024
- 1. Clinical validation of plasma whole genome sequencing for detection of minimal residual disease from solid tumoursCancer Genetics, 2023
- A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanomaEuropean Journal of Cancer, 2022
- Programmable endonuclease combined with isothermal polymerase amplification to selectively enrich for rare mutant allele fractionsChinese Chemical Letters, 2021
- Burden of melanoma in China, 1990–2017: Findings from the 2017 global burden of disease studyInternational Journal of Cancer, 2019
- Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanomaCritical Reviews in Oncology/Hematology, 2015
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- NRAS mutations in primary and metastatic melanomas of Japanese patientsInternational Journal of Clinical Oncology, 2013
- NRAS mutation status is an independent prognostic factor in metastatic melanomaCancer, 2011